Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

InxMed Says FAK Inhibitor Effective against Drug Resistance

publication date: Jun 24, 2020

InxMed (Shanghai), a clinical stage biotech. reported early research data showing its focal adhesion kinase (FAK) small molecule inhibitor was effective in overcoming drug resistance. InxMed's IN10018, a FAK inhibitor, was administered together with a KRAS G12C inhibitor. Although KRAS G12C inhibitors show promise, they are subject to resistance, the company said. InxMed believes IN10018 has the potential to boost the KRAS inhibitor's effect and make other oncology therapies more effective as well. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital